Trial to Assess the Efficacy of Neuroprotective Drugs Administered Topically to Prevent or Arrest Diabetic Retinopathy

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

450

Participants

Timeline

Start Date

February 28, 2013

Primary Completion Date

November 30, 2015

Study Completion Date

November 30, 2015

Conditions
Diabetic Retinopathy
Interventions
DRUG

COLIRIOBCN070660

One drop per eye twice a day during 24 months

DRUG

Placebo

One drop per eye twice a day during 24 months

DRUG

Brimonidine

One drop per eye twice a day during 24 months

Trial Locations (11)

20132

Universita Vita-Salute San Raffaele (USR), Milan

35128

Universita degli Study di Padova(UPadova), Padua

75010

AP - Hopitaux de Paris (AP-HP), Paris

89081

Universitaet Ulm (UUlm), Ulm

Unknown

Syddansk Universitet (SDU), Odense

Gloucestershire Hospitals NHS Foundation Trust (CHGH), Cheltenham

Aston University (UAston)Heart of England NHS Foundation Trust, Birmingham

The University of Liverpool (UOL), Liverpool

3000-548

Aibili - Cec, Coimbra

08035

Institut Catala de la Salut - Hospital Universitari Vall d'Hebron (ICS-HUVH), Barcelona

EC1V2PD

Moorfields Eye Hospital NHS Foundation Trust (MEH), London

Sponsors

Lead Sponsor

All Listed Sponsors
lead

BCN Peptides

INDUSTRY

NCT01726075 - Trial to Assess the Efficacy of Neuroprotective Drugs Administered Topically to Prevent or Arrest Diabetic Retinopathy | Biotech Hunter | Biotech Hunter